CoChat

Scientific and Regulatory Policy Committee: Recommended (“Best”) Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies

Open access
Kerlin, Roy, Bolon, Brad, Burkhardt, John, Francke, Sabine, Greaves, Peter, Meador, Vince, Popp, James · 2016 · Toxicologic Pathology
Cited by 135

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Recommendations (best practices) are provided by the Society of Toxicologic Pathology’s Adversity Working Group for making consistent interpretations of test article–related effects as “adverse” and assigning a “no observed adverse effect level” (NOAEL) in nonclinical toxicity studies. Adverse is a term indicating “harm” to the test animal, while nonadverse indicates lack of harm. Adverse findings in the study reports should be defined in relation to effects on the test species used and within the context of the given study. Test article–related effects should be described on their own merits, and decisions to consider them as adverse or nonadverse should be justified. Related effects may be discussed together; in particular, markers of toxicity that are not in and of themselves adverse ideally should be discussed in conjunction with the causal toxicity to determine adversity. Adverse findings should be identified in subreports (clinical data, pathology data, etc.) if sufficient information is available, and/or in the final study report as individual or grouped findings, but study NOAELs should be established at the level of the overall study report. Interpretations such as “not biologically relevant” or “not toxicologically important” should be avoided unless defined and supported by scientific rationale. Decisions defining adverse findings and the NOAEL in final study reports should combine the expertise of all contributing scientific disciplines. Where possible, use of NOAELs in data tables should be linked to explanatory text that places them in context. Ideally, in nonclinical summary documents, NOAELs from multiple studies are considered together in defining the most important adverse responses in the most sensitive species. These responses are then considered along with an understanding of their likely mechanisms, as well as other information such as variability in species sensitivity, comparative pathology, reversibility and progression, kinetics, and metabolism of the test substance to help assess human risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0192623315623265

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Concordance of the toxicity of pharmaceuticals in humans and in animals

    Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 2×

    “Despite all of these technical advances, considerable differences still remain between the spectrums of harmful effects produced by individual test articles in animals versus the adverse effects induced in people (Greaves, Williams, and Eve 2004; Olson et al. 2000).”
    Background
  • The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man

    Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R., & Rall, D. P. (1970) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt19701113 · Cited by 146 · cited 2×

    “Depending on the test system, some adverse effects may correlate well between animals and humans, while biological responses in other systems are correlated poorly (Dorato and Engelhardt 2005; Freireich et al. 1966; Owens 1962; Schein et al. 1970).”
    Background

Show all 2 references

Cited by

See all 135

Metadata

Authors
Kerlin, R., Bolon, B., Burkhardt, J., Francke, S., Greaves, P., Meador, V., & Popp, J.
Venue
Toxicologic Pathology
Published
2015-12-23
Volume
44
Issue
2
Pages
147-162
ISSN
  • 0192-6233 (ISSN-L)
  • 1533-1601
OpenAlex
W2263224864
Cited by
135
References
2
FWCI
11.90
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scientific and Regulatory Policy Committee: Recommended (“Best”) Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies. https://app.cochat.ai/papers/10.1177/0192623315623265
The paper
Kerlin, R., Bolon, B., Burkhardt, J., Francke, S., Greaves, P., Meador, V., & Popp, J. (2016). Scientific and Regulatory Policy Committee: Recommended (“Best”) Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies. Toxicologic Pathology. https://doi.org/10.1177/0192623315623265

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.